{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T10:05:10Z","timestamp":1779444310949,"version":"3.53.1"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T00:00:00Z","timestamp":1779408000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T00:00:00Z","timestamp":1779408000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100018537","name":"National Science and Technology Major Project","doi-asserted-by":"publisher","award":["2018ZX09735-005"],"award-info":[{"award-number":["2018ZX09735-005"]}],"id":[{"id":"10.13039\/501100018537","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Helongjiang Provincial Key Research and Development Project","award":["GA22C002"],"award-info":[{"award-number":["GA22C002"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Chin Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Psoriasis is an immune-mediated chronic inflammatory skin disease. Existing therapies have limitations, necessitating the development of new treatment approaches. Compound Baixianpi Formula (FFBXP) is a clinically effective topical Chinese herbal formula, but its material basis and mechanism of action remain unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>FFBXP components were identified using UHPLC-Q-Orbitrap HRMS. Core targets and pathways were screened by integrating network pharmacology and transcriptomics analyses. The effects of FFBXP on skin lesions, histopathology, oxidative stress, and inflammatory mediators (IL-17A, IL-23, TNF-\u03b1) were evaluated using a IMQ mouse psoriasis model and a TNF-\u03b1-stimulated HaCaT cell model. Key mechanisms were validated through molecular docking, qRT-PCR, Western blot, and immunofluorescence techniques.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Forty-two active components were identified in FFBXP. In vivo experiments demonstrated that FFBXP significantly improved erythema and skin lesion infiltration in psoriatic mice, while reducing levels of inflammatory cytokines (IL-17A, IL-23, TNF-\u03b1) and oxidative stress markers (MDA). In vitro experiments confirmed that FFBXP dose-dependently inhibited TNF-\u03b1-induced proliferation in HaCaT cells, reduced inflammatory cytokine levels, mitigated oxidative stress, and promoted apoptosis. Network pharmacology and transcriptomics analysis indicated its mechanism involves IL-17, PI3K-AKT, and JAK2-STAT3 signaling pathways. Molecular docking showed that six core active ingredients (berberine, resveratrol, quercetin, catechin, kaempferol, and osthol) had good binding activity with key target proteins. Further mechanism validation revealed FFBXP significantly decrease IL-17A expression and inhibited phosphorylation of downstream PI3K, AKT, JAK2, and STAT3 proteins.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study employs a combined strategy of network pharmacology, transcriptomics, and experimental validation to elucidate for the first time that FFBXP exerts its anti-psoriasis effects by targeting IL-17A and collaboratively inhibiting two key signaling pathways: PI3K-AKT and JAK2-STAT3.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13020-026-01386-0","type":"journal-article","created":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T09:14:48Z","timestamp":1779441288000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Integrating network pharmacology, transcriptomics, and experimental validation: Compound Baixianpi Formula targets IL-17A to inhibit dual PI3K-AKT\/JAK2-STAT3 pathways for psoriasis improvement"],"prefix":"10.1186","volume":"21","author":[{"given":"Lin","family":"Tang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanli","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunli","family":"Gan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinhui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,22]]},"reference":[{"issue":"2","key":"1386_CR1","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1038\/jid.2012.339","volume":"133","author":"R Parisi","year":"2013","unstructured":"Parisi R, Symmons DP, Griffiths CE, et al. Ashcroft, Identification and Management of Psoriasis and Associated ComorbidiTy (IMPACT) project team. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol. 2013;133(2):377\u201385. https:\/\/doi.org\/10.1038\/jid.2012.339.","journal-title":"J Invest Dermatol"},{"issue":"14","key":"1386_CR2","doi-asserted-by":"publisher","first-page":"467","DOI":"10.3238\/arztebl.m2024.0064","volume":"121","author":"U Mrowietz","year":"2024","unstructured":"Mrowietz U, Lauffer F, Sondermann W, et al. Psoriasis as a systemic disease. Dtsch Arztebl Int. 2024;121(14):467\u201372. https:\/\/doi.org\/10.3238\/arztebl.m2024.0064.","journal-title":"Dtsch Arztebl Int"},{"issue":"9583","key":"1386_CR3","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/S0140-6736(07)61128-3","volume":"370","author":"CE Griffiths","year":"2007","unstructured":"Griffiths CE, Barker JN. Pathogenesis and clinical features of Psoriasis. Lancet. 2007;370(9583):263\u201371. https:\/\/doi.org\/10.1016\/S0140-6736(07)61128-3.","journal-title":"Lancet"},{"key":"1386_CR4","doi-asserted-by":"publisher","first-page":"122991","DOI":"10.1016\/j.lfs.2024.122991","volume":"355","author":"D Sugumaran","year":"2024","unstructured":"Sugumaran D, Yong ACH, Stanslas J. Advances in Psoriasis research: from pathogenesis to therapeutics. Life Sci. 2024;355:122991. https:\/\/doi.org\/10.1016\/j.lfs.2024.122991.","journal-title":"Life Sci"},{"issue":"10281","key":"1386_CR5","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1016\/S0140-6736(20)32549-6","volume":"397","author":"CEM Griffiths","year":"2021","unstructured":"Griffiths CEM, Armstrong AW, Gudjonsson JE, et al. Psoriasis. Lancet. 2021;397(10281):1301\u201315. https:\/\/doi.org\/10.1016\/S0140-6736(20)32549-6.","journal-title":"Lancet"},{"issue":"19","key":"1386_CR6","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1001\/jama.2020.4006","volume":"323","author":"AW Armstrong","year":"2020","unstructured":"Armstrong AW, Read C. Pathophysiology, clinical presentation, and treatment of Psoriasis: a review. JAMA. 2020;323(19):1945\u201360. https:\/\/doi.org\/10.1001\/jama.2020.4006.","journal-title":"JAMA"},{"key":"1386_CR7","doi-asserted-by":"publisher","first-page":"1682","DOI":"10.3389\/fimmu.2018.01682","volume":"9","author":"NC Brembilla","year":"2018","unstructured":"Brembilla NC, Senra L, Boehncke WH. The IL-17 family of cytokines in Psoriasis: IL-17A and beyond. Front Immunol. 2018;9:1682. https:\/\/doi.org\/10.3389\/fimmu.2018.01682.","journal-title":"Front Immunol"},{"issue":"7","key":"1386_CR8","doi-asserted-by":"publisher","first-page":"4733","DOI":"10.4049\/jimmunol.181.7.4733","volume":"181","author":"I Kryczek","year":"2008","unstructured":"Kryczek I, Bruce AT, Gudjonsson JE, et al. Induction of IL-17+ T cell trafficking and development by IFN-gamma: mechanism and pathological relevance in psoriasis. J Immunol. 2008;181(7):4733\u201341. https:\/\/doi.org\/10.4049\/jimmunol.181.7.4733.","journal-title":"J Immunol"},{"issue":"12","key":"1386_CR9","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1080\/14712598.2022.2116978","volume":"22","author":"E Rosi","year":"2022","unstructured":"Rosi E, Fastame MT, Di Cesare A, et al. Targeting IL-17A for the treatment of pustular Psoriasis: a comprehensive review. Expert Opin Biol Ther. 2022;22(12):1475\u201387. https:\/\/doi.org\/10.1080\/14712598.2022.2116978.","journal-title":"Expert Opin Biol Ther"},{"issue":"3","key":"1386_CR10","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1358\/dot.2023.59.3.3419557","volume":"59","author":"T Simopoulou","year":"2023","unstructured":"Simopoulou T, Tsiogkas SG, Zafiriou E, et al. Secukinumab, Ixekizumab, Bimekizumab and Brodalumab for Psoriasis and Psoriatic Arthritis. Drugs Today. 2023;59(3):135\u201367. https:\/\/doi.org\/10.1358\/dot.2023.59.3.3419557.","journal-title":"Drugs Today"},{"issue":"1","key":"1386_CR11","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1038\/s41420-023-01566-z","volume":"9","author":"YH Han","year":"2023","unstructured":"Han YH, Feng L, Lee SJ, et al. Depletion of peroxiredoxin II promotes keratinocyte apoptosis and alleviates psoriatic skin lesions via the PI3K\/AKT\/GSK3\u03b2 signaling axis. Cell Death Discov. 2023;9(1):263. https:\/\/doi.org\/10.1038\/s41420-023-01566-z.","journal-title":"Cell Death Discov"},{"key":"1386_CR12","doi-asserted-by":"publisher","first-page":"112781","DOI":"10.1016\/j.intimp.2024.112781","volume":"139","author":"NM Kamel","year":"2024","unstructured":"Kamel NM, El-Sayed SS, El-Said YAM, et al. Unlocking milk thistle\u2019s anti-psoriatic potential in mice: targeting PI3K\/AKT\/mTOR and KEAP1\/NRF2\/NF-\u03baB pathways to modulate inflammation and oxidative stress. Int Immunopharmacol. 2024;139:112781. https:\/\/doi.org\/10.1016\/j.intimp.2024.112781.","journal-title":"Int Immunopharmacol"},{"issue":"1","key":"1386_CR13","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1093\/cei\/uxad025","volume":"213","author":"Y Lin","year":"2023","unstructured":"Lin Y, Zhu X, Li Y, et al. LY294002 ameliorates psoriatic skin inflammation in mice via blocking the Notch1\/Hes1-PTEN\/AKT\/IL-17A feedback loop. Clin Exp Immunol. 2023;213(1):114\u201324. https:\/\/doi.org\/10.1093\/cei\/uxad025.","journal-title":"Clin Exp Immunol"},{"key":"1386_CR14","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1186\/1476-4598-13-209","volume":"13","author":"JG Fern\u00e1ndez","year":"2014","unstructured":"Fern\u00e1ndez JG, Rodr\u00edguez DA, Valenzuela M, et al. Survivin expression promotes VEGF-induced tumor angiogenesis via PI3K\/Akt enhanced \u03b2-catenin\/Tcf-Lef dependent transcription. Mol Cancer. 2014;13:209. https:\/\/doi.org\/10.1186\/1476-4598-13-209.","journal-title":"Mol Cancer"},{"issue":"1","key":"1386_CR15","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s40360-020-00419-0","volume":"21","author":"J Gao","year":"2020","unstructured":"Gao J, Guo J, Nong Y, et al. 18\u03b2-Glycyrrhetinic acid induces human HaCaT keratinocytes apoptosis through ROS-mediated PI3K-Akt signaling pathway and ameliorates IMQ-induced psoriasis-like skin lesions in mice. BMC Pharmacol Toxicol. 2020;21(1):41. https:\/\/doi.org\/10.1186\/s40360-020-00419-0.","journal-title":"BMC Pharmacol Toxicol"},{"issue":"22","key":"1386_CR16","doi-asserted-by":"publisher","first-page":"7014","DOI":"10.3390\/molecules26227014","volume":"26","author":"IK Koycheva","year":"2021","unstructured":"Koycheva IK, Mihaylova LV, Todorova MN, et al. Leucosceptoside A from Devil\u2019s Claw modulates psoriasis-like inflammation via suppression of the PI3K\/AKT signaling pathway in keratinocytes. Molecules. 2021;26(22):7014. https:\/\/doi.org\/10.3390\/molecules26227014.","journal-title":"Molecules"},{"key":"1386_CR17","doi-asserted-by":"publisher","first-page":"3129","DOI":"10.2147\/CCID.S433367","volume":"16","author":"M Megna","year":"2023","unstructured":"Megna M, Potestio L, Ruggiero A, et al. JAK inhibitors in psoriatic disease. Clin Cosmet Investig Dermatol. 2023;16:3129\u201345. https:\/\/doi.org\/10.2147\/CCID.S433367.","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"1386_CR18","doi-asserted-by":"publisher","first-page":"155917","DOI":"10.1016\/j.phymed.2024.155917","volume":"133","author":"Y Lv","year":"2024","unstructured":"Lv Y, Yang L, Mao Z, et al. Tetrastigma hemsleyanum polysaccharides alleviate imiquimod-induced psoriasis-like skin lesions in mice by modulating the JAK\/STAT3 signaling pathway. Phytomedicine. 2024;133:155917. https:\/\/doi.org\/10.1016\/j.phymed.2024.155917.","journal-title":"Phytomedicine"},{"key":"1386_CR19","doi-asserted-by":"publisher","first-page":"111373","DOI":"10.1016\/j.biopha.2021.111373","volume":"137","author":"J Zhu","year":"2021","unstructured":"Zhu J, Yang T, Tang M, et al. Studies on the anti-psoriasis effects and its mechanism of a dual JAK2\/FLT3 inhibitor flonoltinib maleate. Biomed Pharmacother. 2021;137:111373. https:\/\/doi.org\/10.1016\/j.biopha.2021.111373.","journal-title":"Biomed Pharmacother"},{"key":"1386_CR20","doi-asserted-by":"publisher","first-page":"3S","DOI":"10.1177\/12034754221141680","volume":"27","author":"WJ Loo","year":"2023","unstructured":"Loo WJ, Turchin I, Prajapati VH, et al. Clinical implications of targeting the JAK-STAT pathway in psoriatic disease: emphasis on the TYK2 pathway. J Cutan Med Surg. 2023;27:3S-24S. https:\/\/doi.org\/10.1177\/12034754221141680.","journal-title":"J Cutan Med Surg"},{"issue":"3","key":"1386_CR21","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/s40257-015-0128-6","volume":"16","author":"W Talbott","year":"2015","unstructured":"Talbott W, Duffy N. Complementary and alternative medicine for psoriasis: what the dermatologist needs to know. Am J Clin Dermatol. 2015;16(3):147\u201365. https:\/\/doi.org\/10.1007\/s40257-015-0128-6.","journal-title":"Am J Clin Dermatol"},{"key":"1386_CR22","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s13020-018-0174-0","volume":"13","author":"S Meng","year":"2018","unstructured":"Meng S, Lin Z, Wang Y, Wang Z, Li P, Zheng Y. Psoriasis therapy by Chinese medicine and modern agents. Chin Med. 2018;13:16. https:\/\/doi.org\/10.1186\/s13020-018-0174-0.","journal-title":"Chin Med"},{"key":"1386_CR23","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s12906-016-1518-x","volume":"17","author":"M Shen","year":"2017","unstructured":"Shen M, Cui Y, Hu M, Xu L. Quantifying traditional Chinese medicine patterns using modern test theory: an example of functional constipation. BMC Complement Altern Med. 2017;17:44. https:\/\/doi.org\/10.1186\/s12906-016-1518-x.","journal-title":"BMC Complement Altern Med"},{"key":"1386_CR24","doi-asserted-by":"publisher","unstructured":"Li Y. The study on the effect and molecular mechanism of Bai Xian alkaline in the treatment of psoriasis. Central South University for Nationalities, Chinese. 2020. https:\/\/doi.org\/10.27710\/d.cnki.gznmc.2020.000593.","DOI":"10.27710\/d.cnki.gznmc.2020.000593"},{"issue":"02","key":"1386_CR25","first-page":"53","volume":"11","author":"K Wang","year":"2009","unstructured":"Wang K, Yuan Z, Wang J, et al. The effect of osthol on inhibiting HaCaT cell proliferation and inducing apoptosis. Chin J Mod Med. 2009;11(02):53\u20135.","journal-title":"Chin J Mod Med"},{"issue":"03","key":"1386_CR26","first-page":"69","volume":"16","author":"J Wang","year":"2009","unstructured":"Wang J, Wang K, Yuan Z, et al. Observation of the therapeutic effect of snake bed extract patch on 296 cases of psoriasis vulgaris. Chin J Tradit Chin Med Inf. 2009;16(03):69\u201370.","journal-title":"Chin J Tradit Chin Med Inf"},{"issue":"02","key":"1386_CR27","doi-asserted-by":"publisher","first-page":"360","DOI":"10.27710\/d.cnki.gznmc.2020.000593","volume":"36","author":"X Li","year":"2018","unstructured":"Li X, Li P, Wang Y, et al. The application and modern research progress of chicken blood vine in psoriasis. Chin J Tradit Chin Med. 2018;36(02):360\u20134. https:\/\/doi.org\/10.27710\/d.cnki.gznmc.2020.000593.","journal-title":"Chin J Tradit Chin Med"},{"issue":"01","key":"1386_CR28","first-page":"171","volume":"40","author":"X Wu","year":"2024","unstructured":"Wu X, Wang L, Li Y, et al. The mechanism of combined use of Sophora flavescens and Poria cocos in improving psoriasis like skin lesions in mice. Chin Pharmacol Bull. 2024;40(01):171\u201380.","journal-title":"Chin Pharmacol Bull"},{"issue":"06","key":"1386_CR29","doi-asserted-by":"publisher","first-page":"31","DOI":"10.13260\/j.cnki.jfjtcm.010265","volume":"42","author":"H Lv","year":"2011","unstructured":"Lv H. Compound tiger cane cream combined with Xiaoyin decoction for the treatment of 30 cases of psoriasis vulgaris. Fujian Tradit Chin Med. 2011;42(06):31\u20132. https:\/\/doi.org\/10.13260\/j.cnki.jfjtcm.010265.","journal-title":"Fujian Tradit Chin Med"},{"issue":"05","key":"1386_CR30","first-page":"62","volume":"17","author":"Z Yu","year":"2016","unstructured":"Yu Z, Chen L, Gong L. Clinical observation of modified Tuhuai drink in the treatment of 40 cases of psoriasis vulgaris. J Shanxi Univ Tradit Chin Med. 2016;17(05):62\u20133.","journal-title":"J Shanxi Univ Tradit Chin Med"},{"key":"1386_CR31","doi-asserted-by":"publisher","first-page":"154384","DOI":"10.1016\/j.phymed.2022.154384","volume":"105","author":"X Hu","year":"2022","unstructured":"Hu X, Qi C, Feng F, et al. Combining network pharmacology, RNA-seq, and metabolomics strategies to reveal the mechanism of Cimicifugae Rhizoma - Smilax glabra Roxb herb pair for the treatment of psoriasis. Phytomedicine. 2022;105:154384. https:\/\/doi.org\/10.1016\/j.phymed.2022.154384.","journal-title":"Phytomedicine"},{"key":"1386_CR32","doi-asserted-by":"publisher","first-page":"629513","DOI":"10.3389\/fphar.2021.629513","volume":"12","author":"X Zhang","year":"2021","unstructured":"Zhang X, Li X, Chen Y, et al. Xiao-Yin-Fang therapy alleviates psoriasis-like skin inflammation through suppressing \u03b3\u03b4T17 cell polarization. Front Pharmacol. 2021;12:629513. https:\/\/doi.org\/10.3389\/fphar.2021.629513.","journal-title":"Front Pharmacol"},{"key":"1386_CR33","doi-asserted-by":"publisher","first-page":"119680","DOI":"10.1016\/j.jep.2025.119680","volume":"346","author":"Y Lin","year":"2025","unstructured":"Lin Y, Zhao X, Yang Z, et al. Integrating transcriptomics and network pharmacology to reveal the effect and mechanism of Bai-Jie-Jing-Xie ointment on improving skin inflammation of psoriasis. J Ethnopharmacol. 2025;346:119680. https:\/\/doi.org\/10.1016\/j.jep.2025.119680.","journal-title":"J Ethnopharmacol"},{"key":"1386_CR34","doi-asserted-by":"publisher","first-page":"105222","DOI":"10.1016\/j.ebiom.2024.105222","volume":"105","author":"Y Yang","year":"2024","unstructured":"Yang Y, Olah P, Radai Z, et al. Exploratory multi-omics analysis reveals host-microbe interactions associated with disease severity in psoriatic skin. EBioMedicine. 2024;105:105222. https:\/\/doi.org\/10.1016\/j.ebiom.2024.105222.","journal-title":"EBioMedicine"},{"issue":"2","key":"1386_CR35","doi-asserted-by":"publisher","first-page":"282","DOI":"10.3390\/antiox11020282","volume":"11","author":"EC Dobric\u0103","year":"2022","unstructured":"Dobric\u0103 EC, Cozma MA, G\u0103man MA, et al. G\u0103man, the involvement of oxidative stress in psoriasis: a systematic review. Antioxidants (Basel). 2022;11(2):282. https:\/\/doi.org\/10.3390\/antiox11020282.","journal-title":"Antioxidants (Basel)"},{"issue":"17","key":"1386_CR36","doi-asserted-by":"publisher","first-page":"6206","DOI":"10.3390\/ijms21176206","volume":"21","author":"J Ple\u0144kowska","year":"2020","unstructured":"Ple\u0144kowska J, Gabig-Cimi\u0144ska M, Mozolewski P. Oxidative stress as an important contributor to the pathogenesis of psoriasis. J Invest Dermatol. 2020;21(17):6206. https:\/\/doi.org\/10.3390\/ijms21176206.","journal-title":"J Invest Dermatol"},{"issue":"1","key":"1386_CR37","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s40659-020-00316-0","volume":"53","author":"J Gao","year":"2020","unstructured":"Gao J, Chen F, Fang H, et al. Daphnetin inhibits proliferation and inflammatory response in human HaCaT keratinocytes and ameliorates imiquimod-induced psoriasis-like skin lesion in mice. Biol Res. 2020;53(1):48. https:\/\/doi.org\/10.1186\/s40659-020-00316-0.","journal-title":"Biol Res"},{"issue":"1","key":"1386_CR38","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1002\/ptr.8038","volume":"38","author":"D Guo","year":"2024","unstructured":"Guo D, Wang Q, Li A, et al. Liquiritin targeting Th17 cells differentiation and abnormal proliferation of keratinocytes alleviates psoriasis via NF-\u03baB and AP-1 pathway. Phytother Res. 2024;38(1):174\u201386. https:\/\/doi.org\/10.1002\/ptr.8038.","journal-title":"Phytother Res"},{"key":"1386_CR39","doi-asserted-by":"publisher","first-page":"155657","DOI":"10.1016\/j.cyto.2021.155657","volume":"148","author":"ZL Tang","year":"2021","unstructured":"Tang ZL, Zhang K, Lv SC, et al. LncRNA MEG3 suppresses PI3K\/AKT\/mTOR signalling pathway to enhance autophagy and inhibit inflammation in TNF-\u03b1-treated keratinocytes and psoriatic mice. Cytokine. 2021;148:155657. https:\/\/doi.org\/10.1016\/j.cyto.2021.155657.","journal-title":"Cytokine"},{"issue":"5","key":"1386_CR40","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1111\/bph.15983","volume":"180","author":"L Zhang","year":"2023","unstructured":"Zhang L, Ma X, Shi R, et al. Allicin ameliorates imiquimod-induced psoriasis-like skin inflammation via disturbing the interaction of keratinocytes with IL-17A. Br J Pharmacol. 2023;180(5):628\u201346. https:\/\/doi.org\/10.1111\/bph.15983.","journal-title":"Br J Pharmacol"},{"issue":"2","key":"1386_CR41","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1159\/000515767","volume":"238","author":"N Liang","year":"2022","unstructured":"Liang N, Chang W, Peng A, et al. Dermal mesenchymal stem cells from psoriatic lesions stimulate HaCaT cell proliferation, differentiation, and migration via activating the PI3K\/AKT signaling pathway. Dermatology. 2022;238(2):283\u201391. https:\/\/doi.org\/10.1159\/000515767.","journal-title":"Dermatology"},{"key":"1386_CR42","doi-asserted-by":"publisher","first-page":"109747","DOI":"10.1016\/j.biopha.2019.109747","volume":"123","author":"X Yuan","year":"2020","unstructured":"Yuan X, Li N, Zhang M, et al. Taxifolin attenuates IMQ-induced murine psoriasis-like dermatitis by regulating T helper cell responses via Notch1 and JAK2\/STAT3 signal pathways. Biomed Pharmacother. 2020;123:109747. https:\/\/doi.org\/10.1016\/j.biopha.2019.109747.","journal-title":"Biomed Pharmacother"},{"issue":"7","key":"1386_CR43","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1111\/ddg.14124","volume":"18","author":"F Lauffer","year":"2020","unstructured":"Lauffer F, Eyerich K, Boehncke WH, et al. Cytokines of the IL-17 family in psoriasis. JDDG. 2020;18(7):675\u201381. https:\/\/doi.org\/10.1111\/ddg.14124.","journal-title":"JDDG"}],"container-title":["Chinese Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13020-026-01386-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13020-026-01386-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13020-026-01386-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T09:14:51Z","timestamp":1779441291000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13020-026-01386-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,22]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1386"],"URL":"https:\/\/doi.org\/10.1186\/s13020-026-01386-0","relation":{},"ISSN":["1749-8546"],"issn-type":[{"value":"1749-8546","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,22]]},"assertion":[{"value":"24 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The experimental scheme was approved by the Ethics Committee of the School of Pharmacy, Harbin Medical University (Ethics Number: IRB3029725).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"141"}}